PositiveID Corporation Successfully Completes Phase II of Its GlucoChip Glucose-Sensing Microchip for Patients With Diabetes

PositiveID Corporation

announced today it has successfully completed Phase II testing of its GlucoChip™ glucose-sensing microchip for patients with diabetes. In Phase II, the Company, in conjunction with its development partner RECEPTORS LLC ("Receptors"), created and demonstrated a stable and reproducible, closed-cycle continuous glucose-sensing system that consistently functions in the human blood fractions that are relevant to glucose analysis in the human body. The companies have published results from their laboratory testing in a white paper titled, "Development of the Sensing System for an Implantable Glucose Sensor," available at http://www.positiveidcorp.com/files/ImplantableGlucoseSensorWhitePaper.pdf. Demonstration of the self-contained chemical sensing system, based on Receptors' proprietary chemistry platform, requires the interaction of a combination of two components. These components are: 1) a competitive agent/signaling component, which is a dendrimer-boronic acid construct ("DBA"), and 2) a glucose competitive binding environment, which consists of immobilized monosaccharide mimics ("iDIOLs"). The interaction of glucose, the signaling component and the competitive binding environment produce a signal that is proportional to glucose levels. The proof-of-prototype demonstration assays show that the DBA:iDIOL system can produce a measurable response to changing levels of glucose within a physiologically relevant range while functioning under biologically relevant conditions.